Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cytisinicline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 known ✓ | P17787 | 12/20 | 1.00 |
| ▸ | CHRNA4 known ✓ | P43681 | 12/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 9/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 9/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 4/20 | 1.00 |
| ▸ | CHRNA1 | P02708 | 4/20 | 1.00 |
| ▸ | CHRNG | P07510 | 4/20 | 1.00 |
| ▸ | CHRNB1 | P11230 | 4/20 | 1.00 |
| ▸ | CHRND | Q07001 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytisinicline SCHEMBL13595657 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Cytisinicline SCHEMBL8309064 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Cytisinicline SCHEMBL1500421 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Cytisinicline SCHEMBL14870500 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Cytisinicline SCHEMBL161398 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Cytisinicline SCHEMBL19877933 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Cytisinicline SCHEMBL29903945 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Cytisinicline SCHEMBL1500403 | 0.93 | CHRNB2 (0.86) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Cytisinicline SCHEMBL20680760 | 0.91 | CHRNB2 (0.82) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Cytisinicline SCHEMBL20680750 | 0.89 | CHRNB2 (0.80) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115078513-A | Method for detecting black sugar in ethanol-containing beverage | 贵州茅台酒股份有限公司 | 2022-09-20 | — | — | CN | claimed |
| CN-106479315-A | The preparation method of water-saving closet sewage draining valve inwall protective coating | 合肥海宝节能科技有限公司 | 2017-03-08 | — | — | CN | claimed |
| CN-106439550-A | LED flashlight with spectacle frame | 合肥学院 | 2017-02-22 | — | — | CN | claimed |
| CN-106349885-A | Protective coating for inner wall of drainage valve of water-saving toilet bowl | 合肥海宝节能科技有限公司 | 2017-01-25 | — | — | CN | claimed |
| EP-4529924-B1 | TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING CYTISINE | LTS LOHMANN THERAPIE SYSTEME AG (DE) | 2026-02-18 | — | — | EP | disclosed |
| WO-2025077770-A1 | FUSED RING COMPOUND AND USE THEREOF IN KRAS INHIBITOR | 成都海博为药业有限公司 | 2025-04-17 | — | — | WO | disclosed |
| EP-4529924-A1 | TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING CYTISINE | LTS Lohmann Therapie-Systeme AG (DE) | 2025-04-02 | — | — | EP | disclosed |
| US-11911380-B2 | Compositions and use of varenicline for treating dry eye | Oyster Point Pharma, Inc. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230226052-A1 | DRY EYE TREATMENTS | OYSTER POINT PHARMA INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230226053-A1 | DRY EYE TREATMENTS | OYSTER POINT PHARMA INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230226054-A1 | DRY EYE TREATMENTS | OYSTER POINT PHARMA INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230203038-A1 | 4-SUBSTITUED CYTISINE ANALOGUES | THE UNIVERSITY OF BRISTOL (GB) | 2023-06-29 | — | — | US | disclosed |
| US-20030065173-A1 | Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy | O'NEILL BRIAN T (US) | 2003-04-03 | — | — | US | disclosed |
| EP-0870768-B1 | Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents | PFIZER (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-1178045-A1 | Azaindole-ethylamine derivatives as nicotine acetylchlorine receptor binding agents | PFIZER INC. (US) | 2002-02-06 | — | — | EP | disclosed |
| US-6235734-B1 | TOBACCO ADDICTION | PFIZER INC | 2001-05-22 | — | — | US | disclosed |
| US-6235734-B1 | TOBACCO ADDICTION | PFIZER INC | 2001-05-22 | — | — | US | disclosed |
| CN-1295076-A | Sophorine extracting process | JIANGXI TRADITIONAL CHIENSE ME (CN) | 2001-05-16 | — | — | CN | disclosed |
| US-5977131-A | Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents | PFIZER INC. (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0870768-A1 | Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents | PFIZER INC. (US) | 1998-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065173-A1 | Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy | CHRNA5, CHRNA4, CHRNA10 | CHRNB2 12/4885CHRNA4 2/4885CHRNB4 4/4885 |
| US-20230226054-A1 | DRY EYE TREATMENTS | PDE6D, CRYAB, ALDH1A2 | CHRNB2 1787/4885CHRNA4 2137/4885CHRNB4 1806/4885 |
| US-20230203038-A1 | 4-SUBSTITUED CYTISINE ANALOGUES | CES2, CDA, PCYT1A | CHRNB2 48/4885CHRNA4 7/4885CHRNB4 21/4885 |
| US-11911380-B2 | Compositions and use of varenicline for treating dry eye | CHRNA7, ACHE, HTR7 | CHRNB2 30/4885CHRNA4 34/4885CHRNB4 38/4885 |
| US-20230226053-A1 | DRY EYE TREATMENTS | PDE6D, CRYAB, ALDH1A2 | CHRNB2 1787/4885CHRNA4 2137/4885CHRNB4 1806/4885 |
| US-20230226052-A1 | DRY EYE TREATMENTS | PDE6D, CRYAB, ALDH1A2 | CHRNB2 1787/4885CHRNA4 2137/4885CHRNB4 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.